BMY: Might Be Approaching A Bottom In 2024
BMY reports in Q4 results next week, below I discuss what investors should consider heading into earnings. The recent $20bn (estimated) acquisition spree in Q4 may have signalled a weak drug pipeli...
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Bristol Myers Squibb (BMY) settling at $49.57, representing a -1.08% change from its previous close.
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Bristol Myers Squibb (BMY) closed at $50 in the latest trading session, marking a -0.62% move from the prior day.
Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal
I discuss a cheap Big Pharma stock and its performance in the market. I provide an overview of the stock's history, including its R&D cycle, dividend and yield on cost history, and valuation. With ...
Bullish Continuation in '24? 3 Market Areas to Watch
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also
Shares of Bristol-Myers Squibb Company have bottomed and offer an enticing valuation. Bristol-Myers Squibb has a highly profitable business, strong cash flow, and a low P/E ratio. Bristol-Myers is ...
Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market
Bristol Myers Squibb (BMY) concluded the recent trading session at $51.28, signifying a -0.98% move from its prior day's close.
Bristol-Myers CEO Says the Company Is in Transition
Bristol-Myers CEO Christopher Boerner says the company is in transition, but he's excited about the strength of recent deals and drugs in their pipeline. He speaks on "Bloomberg Markets" from San F...
Bristol Myers Squibb CEO: With KarXT we'll be able to deliver good accuracy without the side effects
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk recent acquisitions made by the company, what's ahead for BMY and much more.
We got a number of important drugs from the Celgene acquisition, says Bristol Myers Squibb CEO
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk recent acquisitions made by the company, whats ahead for BMY and much more.
Bristol-Myers CEO talks new acquisitions: 'We are writing the next chapter of this company'
Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's slew of recent acquisitions in a Monday interview with CNBC's Jim Cramer.
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)
3 Dividend Stocks for Strong Returns in 2024 and Beyond
The S&P 500 closed out a strong year, up more than 20% for 2023. For investors looking for the best dividend stocks in the New Year and beyond, we recommend companies with durable competitive advan...
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.
Bristol-Myers Squibb downgraded on mixed sales performance of new products amid loss of exclusivity concerns
Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has been downgraded by Bank of America (BoA) analysts given the mixed performances of the drugmaker's newly launched products and lack of clari...
Related Companies